Phase 4
N=10
Comparison of Keppra and Clonidine in the Treatment of Tics
Tic Disorders · Tourette Syndrome
Bottom Line
View on ClinicalTrials.gov: NCT00370838 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Sep 2011
Primary outcome: Primary: Yale Global Tic Severity Scale (YGTSS): — 45.2; 48.7; 48.8; 43.1 scores on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Levetiracetam (Drug); Clonidine (Drug)
- Age
- Pediatric, Adult · 7+ yrs
- Sex
- All
- Sponsor
- Harvey S. Singer
- Primary completion
- Jul 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Yale Global Tic Severity Scale (YGTSS): |
45.2; 48.7; 48.8; 43.1 | — |
| PRIMARY Total Tic Score |
22.7; 25.2; 23.6; 21.8 | — |
| SECONDARY Clinical Global Impression-Improvement (CGI-I): |
4.1; 4.1; 4.1; 4 | — |
| SECONDARY Child Yale-Brown Obsessive Compulsive Scale (CY-BOCS): |
4.7; 3.1; 2.2; 3.2 | — |
| SECONDARY DuPaul Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale: |
12.5; 12.6; 12.7; 11.9 | — |
| SECONDARY Multidimensional Anxiety Scale for Children (MASC): |
32.9; 25.2; 27.5; 25 | — |
| SECONDARY Modified Pittsburgh Side Effect Scale |
2.1; 3.4 | — |
Summary
The goal of this study is to confirm that levetiracetam has a better tic-suppressing profile than that of the widely used tic-suppressing medication, clonidine. More specifically, the investigators hypothesize that in a 15 week placebo run-in, double-blind, medication cross-over trial; levetiracetam will be more effective and have fewer side-effects than clonidine.
Eligibility Criteria
Inclusion Criteria
Patients will be included in this study if they meet the following criteria:
- Tourette syndrome criteria based on the TS Classification Study Group [1993], which includes onset before 18 years, multiple involuntary motor tics, one or more vocal tics, a waxing and waning course, the gradual replacement of old symptoms with new ones, the presence of tics for more than one year, the absence of other medical explanations for tics, and observation of tics by a reliable examiner;
- Age 7 to 19 years, either gender;
- Observable tics, achieving a minimum score of > 22 on the Total Tic score of Yale Global Tic Severity Scale (YGTSS);
- Tic symptoms severe enough to warrant therapy;
- The concurrent use of other tic-suppressing medications will be permitted, if the subject has been on a stable dose for more than three weeks and agrees to maintain a constant dosage throughout the study;
- Tics are not controlled with current medication or individuals are tic suppressing drug naive.
Exclusion Criteria
Exclusion criteria include the following:
- Secondary tics;
- Significant medical illness
- Current major depression, generalized anxiety disorder, separation anxiety disorder, psychotic symptoms (based on clinical evaluation), pervasive developmental disorder, autism, mental retardation (I.Q. less than 70), anorexia/bulimia, or substance abuse. Subjects with co-morbid ADHD, obsessive compulsive disorder (OCD), and conduct disorder will not be excluded;
- pregnancy;
- Hypersensitivity to levetiracetam or clonidine;
- baseline weight of less than 25 kilograms.
Data sourced from ClinicalTrials.gov (NCT00370838). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.